Research Paper Volume 11, Issue 23 pp 11124—11135
JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
Figure 3. JAK1 mRNA levels associated with tumor infiltrating lymphocytes. (A) The average expression of the LYM metagene signature (SASH3, CD53, NCKAP1L, LCP2, IL10RA, PTPRC, EVI2B, BIN2, WAS, and HAVCR2) in each breast cancer sample from TCGA is shown relative to JAK1 mRNA. (B) JAK1 mRNA levels are shown relative to levels of tumor infiltrating lymphocytes in 57 breast cancer samples.